US FDA Approves Subcutaneous Opdivo, Extending Key BMS Franchise Into 2030s

Injection Cleared 10 Years After I.V. Product

 
• By Mandy Jackson
  
Opdivo Qvantig is crucial to Bristol's post-Opdivo loss of exclusivity revenue (Shutterstock)

More from Strategy

More from Scrip